Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,040 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.
Fedoriw A, Rajapurkar SR, O'Brien S, Gerhart SV, Mitchell LH, Adams ND, Rioux N, Lingaraj T, Ribich SA, Pappalardi MB, Shah N, Laraio J, Liu Y, Butticello M, Carpenter CL, Creasy C, Korenchuk S, McCabe MT, McHugh CF, Nagarajan R, Wagner C, Zappacosta F, Annan R, Concha NO, Thomas RA, Hart TK, Smith JJ, Copeland RA, Moyer MP, Campbell J, Stickland K, Mills J, Jacques-O'Hagan S, Allain C, Johnston D, Raimondi A, Porter Scott M, Waters N, Swinger K, Boriack-Sjodin A, Riera T, Shapiro G, Chesworth R, Prinjha RK, Kruger RG, Barbash O, Mohammad HP. Fedoriw A, et al. Cancer Cell. 2019 Jul 8;36(1):100-114.e25. doi: 10.1016/j.ccell.2019.05.014. Epub 2019 Jun 27. Cancer Cell. 2019. PMID: 31257072 Free article.
Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell-Mediated Antitumor Immune Responses.
Fedoriw A, Shi L, O'Brien S, Smitheman KN, Wang Y, Hou J, Sherk C, Rajapurkar S, Laraio J, Williams LJ, Xu C, Han G, Feng Q, Bedford MT, Wang L, Barbash O, Kruger RG, Hwu P, Mohammad HP, Peng W. Fedoriw A, et al. Cancer Immunol Res. 2022 Apr 1;10(4):420-436. doi: 10.1158/2326-6066.CIR-21-0614. Cancer Immunol Res. 2022. PMID: 35181787 Free PMC article.
The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin.
Wang Y, Bernhardy AJ, Cruz C, Krais JJ, Nacson J, Nicolas E, Peri S, van der Gulden H, van der Heijden I, O'Brien SW, Zhang Y, Harrell MI, Johnson SF, Candido Dos Reis FJ, Pharoah PD, Karlan B, Gourley C, Lambrechts D, Chenevix-Trench G, Olsson H, Benitez JJ, Greene MH, Gore M, Nussbaum R, Sadetzki S, Gayther SA, Kjaer SK; kConFab Investigators; D'Andrea AD, Shapiro GI, Wiest DL, Connolly DC, Daly MB, Swisher EM, Bouwman P, Jonkers J, Balmaña J, Serra V, Johnson N. Wang Y, et al. Cancer Res. 2016 May 1;76(9):2778-90. doi: 10.1158/0008-5472.CAN-16-0186. Cancer Res. 2016. PMID: 27197267 Free PMC article.
In Vitro and In Vivo evaluation of a novel folate-targeted theranostic nanoemulsion of docetaxel for imaging and improved anticancer activity against ovarian cancers.
Patel NR, Piroyan A, Ganta S, Morse AB, Candiloro KM, Solon AL, Nack AH, Galati CA, Bora C, Maglaty MA, O'Brien SW, Litwin S, Davis B, Connolly DC, Coleman TP. Patel NR, et al. Cancer Biol Ther. 2018 Jul 3;19(7):554-564. doi: 10.1080/15384047.2017.1395118. Epub 2018 May 8. Cancer Biol Ther. 2018. PMID: 29737910 Free PMC article.
Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth.
Gritsina G, Xiao F, O'Brien SW, Gabbasov R, Maglaty MA, Xu RH, Thapa RJ, Zhou Y, Nicolas E, Litwin S, Balachandran S, Sigal LJ, Huszar D, Connolly DC. Gritsina G, et al. Mol Cancer Ther. 2015 Apr;14(4):1035-47. doi: 10.1158/1535-7163.MCT-14-0800. Epub 2015 Feb 2. Mol Cancer Ther. 2015. PMID: 25646015 Free PMC article.
Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer.
Kurimchak AM, Shelton C, Duncan KE, Johnson KJ, Brown J, O'Brien S, Gabbasov R, Fink LS, Li Y, Lounsbury N, Abou-Gharbia M, Childers WE, Connolly DC, Chernoff J, Peterson JR, Duncan JS. Kurimchak AM, et al. Cell Rep. 2016 Aug 2;16(5):1273-1286. doi: 10.1016/j.celrep.2016.06.091. Epub 2016 Jul 21. Cell Rep. 2016. PMID: 27452461 Free PMC article.
Network analysis identifies an HSP90-central hub susceptible in ovarian cancer.
Liu H, Xiao F, Serebriiskii IG, O'Brien SW, Maglaty MA, Astsaturov I, Litwin S, Martin LP, Proia DA, Golemis EA, Connolly DC. Liu H, et al. Clin Cancer Res. 2013 Sep 15;19(18):5053-67. doi: 10.1158/1078-0432.CCR-13-1115. Epub 2013 Jul 30. Clin Cancer Res. 2013. PMID: 23900136 Free PMC article.
Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target.
Perales-Puchalt A, Svoronos N, Rutkowski MR, Allegrezza MJ, Tesone AJ, Payne KK, Wickramasinghe J, Nguyen JM, O'Brien SW, Gumireddy K, Huang Q, Cadungog MG, Connolly DC, Tchou J, Curiel TJ, Conejo-Garcia JR. Perales-Puchalt A, et al. Clin Cancer Res. 2017 Jan 15;23(2):441-453. doi: 10.1158/1078-0432.CCR-16-0492. Epub 2016 Jul 19. Clin Cancer Res. 2017. PMID: 27435394 Free PMC article.
4,040 results